Australia's most trusted
source of pharma news
Wednesday, 18 March 2026
Posted 18 March 2026 AM
MSD's Keytruda is hanging onto the title of the world's best-selling drug with a handsome haul of almost US$32 billion in 2025 but the win could be based on a technicality.
At first glance, Keytruda appears to be holding a comfortable lead. It's closest competitor, Eli Lilly's Mounjaro is in second place on US$23 billion.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.